Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway
Semaglutide exerts inhibitory actions on OSCC and may induce apoptosis in OSCC cells via the P38 MAPK signaling pathway. This study has significant implications for the treatment of patients with diabetes who are also afflicted by OSCC.
Authors
- Bin Cheng (ORCID: https://orcid.org/0000-0001-7288-806X)
- Can Wang (ORCID: https://orcid.org/0000-0001-7347-9233)
- Zhenhua Wu (ORCID: https://orcid.org/0000-0003-4552-883X)
- Jiaying Zhou (ORCID: https://orcid.org/0000-0003-1921-7392)
- Yulei Huang
Institutions
- Key Laboratory of Guangdong Province (CN)
- Stomatology Hospital (CN)
- Guangdong Provincial People's Hospital (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1007/s00432-025-06154-5
- Citations
- 10
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.95